Heron Therapeutics: Cash Is A Problem Again (NASDAQ:HRTX)
Portra/E+ via Getty Images It’s been almost a year since my previous article on Heron Therapeutics (NASDAQ:HRTX) and while the company made progress, the stock is sitting near 52-week lows and is down 60% since […]
